Peptide Initiative

Peptide profile · Hormone Support

Triptorelin

GnRH agonist that helps manage prostate cancer, endometriosis, and early puberty by controlling sex hormones

Strong human trialsFDA approved for this use
2-3 hoursHalf-life (free peptide); 2-4 weeks (depot pamoate formulations)
~100%Bioavailability (intramuscular/subcutaneous injection)
1311.4Molecular weight, g/mol

Molecular formula

C64H82N18O13

CAS number
57773-63-4
PubChem
25074470
Developed · 1982
Debiopharm Research Team, Debiopharm (licensed from Tulane University in 1982)

Amino acid sequence

pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2

Hormone RegulationSuppresses testosterone levels in prostate cancer patients

9.4

Cancer ManagementReduces symptoms of endometriosis including pelvic pain

9.0

Endometriosis ReliefSlows progression of central precocious puberty in children

8.7

Ratings out of 10.

3.75 – 22.5mg

Every documented dose level

PhaseDoseFrequency
Ongoing while indicated3.75 mgOnce every 4 weeks
Ongoing while indicated11.25 mgOnce every 12 weeks
Ongoing while indicated22.5 mgOnce every 24 weeks
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for managing advanced prostate cancer when combined with other treatments & relieving severe endometriosis pain and symptoms

Best for

  • Managing advanced prostate cancer when combined with other treatments

    Triptorelin is particularly well-suited for individuals focused on managing advanced prostate cancer when combined with other treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Relieving severe endometriosis pain and symptoms

    Triptorelin is particularly well-suited for individuals focused on relieving severe endometriosis pain and symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Delaying puberty development in children with early sexual maturation

    Triptorelin is particularly well-suited for individuals focused on delaying puberty development in children with early sexual maturation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for hormone support supportConsult your healthcare provider for alternatives to Triptorelin based on your specific needs and medical history
Alternative hormone-supporting peptidesKisspeptin-10GonadorelinPT-141 (Bremelanotide)
Non-peptide hormone supportClomiphene citrateAnastrozoleLifestyle modifications (sleep, exercise)

Do not use if

  • Pregnancy (can affect fetal development)
  • Undiagnosed vaginal bleeding
  • Known hypersensitivity to GnRH agonists
  • Severe untreated depression
  • Active spinal cord compression in prostate cancer (requires urgent decompression)

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Triptorelin use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare Triptorelin with similar peptides to find the best fit for your goals.

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

The Triptorelin injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.

Emergency signs first, then what this page and MedlinePlus say.

Triptorelin (GnRH agonist) has extensive FDA-approved safety data spanning decades for prostate cancer, endometriosis, and precocious puberty indications.

Initial testosterone surge upon initiation ("flare reaction") can worsen prostate cancer or spinal cord compression symptoms, requiring careful patient monitoring in first 1-2 weeks and use of androgen antagonists in high-risk patients.

Hypogonadal effects including hot flashes, sexual dysfunction, and bone loss develop predictably with chronic GnRH suppression; bone density monitoring is recommended in patients on therapy >6 months.

Triptorelin safety is well-established from Phase 3 prostate cancer trials and 25+ years post-market use in 400,000+ patients. Reversibility of hypogonadal effects within 2-4 months of discontinuation supports its tolerability profile.

Off-label use in other hormone-dependent conditions carries similar pharmacological risks; baseline testosterone, FSH/LH, and PSA monitoring before initiation establishes individual risk profile.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Triptorelin
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Triptorelin should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeAntiandrogens (like bicalutamide) for prostate cancer treatment — May be used together under medical guidance.
  • SafeNonsteroidal anti-inflammatory drugs (NSAIDs) for pain management — May be used together under medical guidance.
  • SafeBone-protective medications (bisphosphonates) during long-term therapy — May be used together under medical guidance.

With medications

  • CautionOther GnRH agonists or antagonists — Use with caution—discuss with your healthcare provider.
  • CautionCertain antifungal medications that inhibit liver metabolism — Use with caution—discuss with your healthcare provider.
  • CautionMedications that require unaltered hormone levels — Use with caution—discuss with your healthcare provider.

With supplements

  • SafeMultivitamins — Generally safe to take alongside Triptorelin. Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Strong human trials · first signs days 1-7

Evidence level

Strong human trials

(Phase 3 or FDA approved)

100/100

Regulatory status

FDA approved for this use

Onset of effects

Moderate

(1-2 weeks)


How it works

Triptorelin tricks your pituitary gland into thinking it's getting the wrong signal.

For the first few days, it actually stimulates hormone production, but your body quickly adapts and shuts down the whole hormone factory. This causes testosterone to plummet (great for prostate cancer) or estrogen to drop (great for endometriosis).

It's like sending your body's hormone production system into a controlled hibernation.

The deeper mechanism

Triptorelin is a synthetic decapeptide (10-amino acid sequence: pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2) that acts as a potent GnRH agonist with high receptor affinity and prolonged receptor-binding capacity compared to native GnRH.

Upon injection, triptorelin binds GnRH receptors on gonadotroph cells in the anterior pituitary, initially causing acute release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH)—the 'flare' phase lasting 1-2 weeks.

Continuous triptorelin exposure (via depot formulations) leads to receptor desensitization and downregulation through uncoupling of G-protein signaling and receptor internalization, resulting in paradoxical suppression of LH and FSH secretion.

This suppression eliminates stimulation of testosterone production in Leydig cells (in men) and estrogen synthesis in ovarian granulosa cells (in women).

Testosterone suppression reaches castration levels (<0.7 nmol/L) within 3-4 weeks in most patients, with sustained suppression continuing as long as depot medication is administered.

The decapeptide modifications provide enhanced proteolytic resistance and prolonged half-life compared to GnRH, enabling once-monthly (3.75mg), quarterly (11.25mg), or 6-monthly (22.5mg) depot formulations through esterification with pamoate or embonate salts.


What to expect

  1. Days 1-7

    What you might notice

    • Initial hormone surge (flare) may occur as the pituitary gland resets
    • Some patients notice increased hot flashes, mood swings, or temporary hormone-related symptoms

    What's normal

    • Initial response to Triptorelin is beginning at the cellular level
    • Different individuals experience Triptorelin's onset at different rates
    • Transient systemic effects from initial Triptorelin exposure are common

    What's next

    • Maintain consistent Triptorelin administration as prescribed
    • Document subjective effects and physical markers daily
    • Schedule a check-in with your provider about initial observations
  2. Weeks 2-4

    What you might notice

    • The flare effect wears off as the pituitary stops responding
    • Testosterone or estrogen levels begin dropping significantly
    • Hot flashes often peak during this time but gradually improve

    What's normal

    • Triptorelin is now achieving steady-state pharmacokinetics
    • Measurable changes aligned with Triptorelin's mechanism may appear
    • Initial adjustment effects typically resolve by this point

    What's next

    • Maintain Triptorelin dosing exactly as established
    • Track progress toward intended outcomes in detail
    • Review lab work or biomarker changes with your healthcare team
  3. Months 2-3

    What you might notice

    • Hormone levels stabilize at suppressed levels
    • Sexual side effects become more noticeable
    • In prostate cancer patients, PSA levels drop
    • Most mood-related side effects settle

    What's normal

    • Full therapeutic effects of Triptorelin are well-characterized at this point
    • Maintenance of Triptorelin's therapeutic effects is typical
    • Tolerance patterns with Triptorelin are generally stable over months

    What's next

    • Comprehensive assessment of Triptorelin efficacy should be conducted
    • Discuss long-term continuation, cycling, or protocol modifications
    • Continue regular monitoring of relevant biomarkers or symptoms

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Triptorelin over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

311 registered studies, 43 still enrolling.

311registered studies
43recruiting now
134phase 3 or 4
67with published results

By phase

Phase 3

68

Phase 2

57

Phase 4

54

Phase 2/3

12

Phase 1

4

Early Phase 1

2

Phase 1/2

2

No phase

112

A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.

What kind of research

Gave the drug

285

Records only

26

About 73,119 people took part in the studies that actually administered Triptorelin. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.


Most recent

  • NCT07782840 Phase 2Not Yet Recruiting40 enrolled

    QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy

    Hebei Medical University Fourth Hospital

  • NCT07751133 Phase 3Not Yet Recruiting1,500 enrolled

    Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer

    University College, London

  • NCT07455903 Phase 2Recruiting50 enrolled

    Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

    Baptist Health South Florida

See all 311 trials for Triptorelin

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Triptorelin is named as an intervention; studies that only mention it in passing are not.

How long does it take for triptorelin to work?

Most people see the suppression effects start within 1-2 weeks, with full suppression by 4 weeks. However, a temporary hormone surge called a 'flare' can happen first, making symptoms temporarily worse before they improve.

Can I stop taking triptorelin whenever I want?

No, stopping suddenly without talking to your doctor can be dangerous, especially for prostate cancer. Your testosterone will rapidly return to normal levels. Always work with your doctor to plan when and how to stop treatment.

Will triptorelin side effects go away after I stop?

Most side effects improve as your hormone levels return to normal after stopping, usually within weeks to months. However, some bone loss may be permanent, so your doctor might recommend bone-strengthening treatments.

Is triptorelin safe for long-term use?

Yes, triptorelin has been used safely for over 40 years. Long-term safety concerns mainly involve bone loss (osteoporosis), so doctors monitor this and may recommend preventive treatments like calcium, vitamin D, and bisphosphonates.

What's the difference between monthly and 6-month injections?

Both work the same way medically. The 6-month version is just more convenient because you need fewer injections per year. Your doctor will help you decide which schedule fits your lifestyle and medical needs best.

Can women use triptorelin?

Yes, women with endometriosis use triptorelin to reduce estrogen and relieve pain. It's also used in certain fertility treatments and for other hormone-sensitive conditions in women.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Triptorelin, on one page.

Triptorelin dosing protocol

Medical disclaimer

Triptorelin is FDA approved for the use described here. It is a prescription medication that should only be started, adjusted, or stopped under the supervision of a qualified healthcare provider. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 11, 2026

3.75 – 22.5 mg Once every 4 weeks or once every 12 weeks or once every 24 weeks · onset 1-2 weeks
Open the Triptorelin calculatorTriptorelin calculator